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Objcchcs. The aimof this study was to objectively evaluate the 
effactsot tntermittent admintstratton f transdermal itrogtycerin 
MI olfoflort tokrance, frequency of angina1 attacks and p-arm of 
silent i&en& events that occur during normal daily octivitia. 
Buckgrowuf. Previms studies have shown that transdcrmal 
ailmglycerin p&ches reduce the incidence af angiaal Ma& aad 
imprave xercise cap+ when given intermittently. flawever, no 
car&ally controtted studi are available on the effects of lhpse 
pnparrdbns (and lheir d&g schedule) on the ocrurrew of 
%ilent” isehemie evenlr daring unrest&led daily a&it&. 
MeINs. Twelve men attb chmnh stable an&a, a @he 
exert& test rem11 and star&ant earcmvv artan disease com- 
nkted a mndam&d. d&a-Gtd. da&-con&led trial in . 
khicb patches were worn either eoatiaawsly or with overnight 
(8 b] removal. llae eflecte of treatment were objeerlvely d 
_ _-___ ~__ 
The conlroversies concerning the role of transdermal nitro- 
glycerin preparations for the treatment of angina pectoris 
(l-6) arise from the evidence that even though these agents 
afford some beneht dmingtbe tirst phase of treatment (7-10). 
they very rapidly induce tolerance in many patients (4. I I- 
13). Because the loss of efi?cacy occurs despite relatively 
constant plasma levels, the development of tolerance has 
been related to the pharmacokinetic profile of these drugs. 
which results in active plasma levels for prolonged periods of 
time (14). 
The results of prevbus studies (15-20) employing inrer- 
mittent dosing schedules and assessing drug efficacy by 
exercise testing and subjective symptoms seem to support 
this hypothesis. However, little information is available as to 
whether intermittent transdermal nitrates provide sufficient 
protection against the silent ischemic events that occur 
during daily activity (6,21,22) and invariably outnumber 
anginaI attacks (23-27). Furthermore, it is still debated 
whether discontinuous treatment results in exacerbation of 
ischemia in the drug-free periods. 
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t592. accepkd IlIly 14, 1932. 
m: Enrico Ror~etti. MD, Dwirione di Cardin- 
lngia, Ospcdak San R&ele, Vii Olgeltina MI. 20132 Milan. Italy. 
Methods 
Sludy paltenta. The original study group comprised 14 
men (mean age 63 -C 6 years, range 54 to 72) with chronic 
stable angina and significant coronary disease (&O% diam- 
eter reduction) documented by both coronary arteriography 
and thallium-201 stress/rest myocardial perfusion scintigm- 
phy. In all 14 patients, a treadmill exercise test (modibed 
Bruce protocol) resulted in angina or significant ischemic ST 
segment depression (rl mm rectilinear or downsloping), or 
both. Evidence of daily episodes of &hernia (=I/24 h) 
during unrestricted activities was also obtained in all patients 
by Halter monitoring. Patients with recent (s3 months) 
myocardial infarction, unstable or variant angina or electro- 
cardiographic (ECG) abnormalities at rest preventing the 
interpretation of ST segment changes were excluded. 
All antianginal medications were withdrawn a5 days 
before the beginning of the study and only sublingual nitro- 
glycerin was allowed for tbe relief of angina. The clinical 
characteristics of the study patients are listed in Table I. 
Study design. We conducted a randomized, doubleblind, 
placebo-controlled crossover trial organized in two phases 
(immediate and maintenance) preceded by a 5-day washout 
period and lasting 3 and 24 days, respectively. 
The c%cacy of transdermal nitroglycetin on exercise end 
points was verifier! on days 1 and 3 of the immediate phase in 
which an active (lO-mg nitroglycerin) or matcbinf piacebo 
Table 1. Clinical Characteristics of the Original Study Group of 14 Men 
All&l 
Verrelr With CAD 
Age D”rallO” *ttaclrsiweer Previaus by Angiogmphy 
Et No. (Yr) (mo) (no.1 MI “to Diabetes (no.) 
I 61 60 IS - - - I 
2 63 3 
3 65 MI 
4 70 c 
5 62 12 
6 67 156 
7 55 8 
a 69 12 
9 57 6 
IO 67 b4 
II 57 3 
12 12 16 
13’ 54 I 
5 Inf - 2 
6 Inf + + 3 
10 - + 2 
I nQ - 2 
I5 - + I 
4 Jnf - + 3 
7 Inf - 3 
3 Ant + + 2 
12 nQ - 2 
I Ant - + 2 
3 - + 2 
5 - - 2 
14* 62 64 17 1nf + + 3 
*Patient (R) withdrew from the study kcawe of wet htadach:. AnI = anwior: CAD = c~mnay artery 
disease; Hln = hypertension; Inf = inferior; Ml = myocardia! infarction: nQ = nonQ wave iniarction: - = no: 
+ = yer. 
patch was applied in a randomized, %uble-blind fashion at 
8 AM. To avoid potential carryover effects from active treat- 
ment, patients always received a placebo patch on day 2. 
The maintenance uhase consisted of two periods of I2 
days each during wh&h transdenral nitroglycerin (10 mg) 
was eiven either continuouslv or intermittentlv. In each 
pariG, the patients applied two patches a day, the first from 
8 AM to midnight to cover the entire active period of the 
patients anu the second from midnight to 8 AM. During the 
continuous phase, both morning and evening patches were 
active, whereas during the intermittent phase, the morning 
patch was active and the evening patch was placebo. There- 
fore, assuming a constant and complete release of the drug 
administered during the two periods, the nitroglycerin dose 
was 10 and 6.6 mg, respectively, over 24 h. Patients were 
randomized to the two treatment periods in a double-blind 
crossover design. 
Exercise testlog. Exercise stress tests were performed at 
the end of the washoul period, on days 1 and 3 of the 
immediate phase and on day I2 of each period of the 
maintenance phase. Each test was carried out on the tread- 
mill in the fasting state at noon 4 h afler the morning patch 
application, according to the modified Bruce protocol. All 
tests were performed by using a computer-assisted unit 
(Case 12, Marquette Electronics Inc). The 12-lead ECG and 
bload pressure were recorded every minute throughout 
exercise and recovery. Loads III, V, and V, were continu- 
ousiv monitored and the levei of the ST senment was 
automatically calculated in all 12 leads, at the 5 point and 
80 ms thereafter, following signal averaging over 32 beats. 
Exercise was discontinued whenever ~1.5 mm of horizontal 
or downsloping ST segment depression, angina, fatigue, 
severe arrhythmiaor 210 mm Hg decrease in blood pressure 
occurred. 
For each test, systolic blood pressure, heart rate and 
rate-pressure product were recorded at rest, at 1 mm of ST 
segment depression and at peak exercise. Time to I mm of 
ST segment depression and to peak exercise was also 
evaluated. 
Halter monitoring. Twenty-four hour Holter recordings 
were netformed on davs I and 3 of the immediate chase. as 
well as on days 12 and 24 of the maintenance treatment 
period and were started at 8 AM. The two ECG leads 
exhibiting maximal ST segment depression during the exer- 
cise test were used for the ambulatory study. Leads with 
abnormal Q waves were avoided and recordings were made 
in the supine, prone, standing and siring positions to estab- 
lish the effects of postural changes on the ST segment. 
Patients were instructed to keep a daily diary, descrit:ng 
their activities and rerording the time and duration of angina1 
episodes and nitroglycerin consumption. Painful episodes 
were identified from the event marker operated by the 
patients and from diary cards. The two ECG leads were 
continuously recorded on dual-channel amplitude-modu- 
lated recorders (Series 85M), Marquette Electronics Inc.). 
Episodes of ST segment depression were identified both by 
reviewing tapes on a memory oscilloscope at a playback 
speed of60 times the real time and by analyztng dual-channel 
high resolution ST trends produced by the internal algorithm 
of the processing unit (Series 8OOOff. Marquette Electronics 
Inc.). For each episode identified, ECG strips were printed 
at a paper speed of 25 mm/s together with the preceding and 
following minute of recording. Only episodes of transient 
rectilinear or downsloping ST segment depression of 2 I mm 
were considered significant. 
liatu analysis. The end poims achie,ved in each treatment 
phase were compared with those obtained with placebo. For 
all tested variables, data were expressed as mean + SD. 
Statistical significance was evaluated by paired two-tailed 
Student r tests. A p value < 0.05 was considered statistically 
sigaiftcarlt. 
Results 
Of the 14 patients, 12 completed the trial and 2 discon- 
tinued active treatment because of severe headache. 
Hamodyuamic aEar% at rest (T&la 2). In the immediate 
treatment phase, systolic blood pressure was signihcantly 
(p < 0.01) lower aRer active patch application (121 + 
9 mm Hg) than after both placebo administration (136 + 
12 mm Hg) and the no patch period (145 t 15 mm Hg). In 
the same period. heart rate levels were higher (82 + 9 beats/ 
mitt) than during no patch and placebo (70 2 7 and 71 + 
8 beats&r, respectively, p < 0.01). 
In the maintenance treatment phase, a decrease in sys- 
tolic blood pressure was only noted during intermittent 
therapy, when this variable was lower (120 r 12) than on no 
treatment (I45 + I5 mm Hg, p < 0.05). R&rive to no 
treatment (70 k 7 beatslmin), heart rate also increased 
signiticantly during intermittent therapy (85 f 8 beats/min, 
p < 0.01); furthermore, heart rate was higher during inter- 
mittent than during continuous dosing (74 k 6 beats/min), 
although the difference was not statistically significant. Fi- 
nally, the values of rate-pressure product were not signiti- 
candy dierent in the different phases of maintenance treat- 
ment. 
Eaarehre tnkranca. In all patients, the exercise test result 
was positive in the no patch period and remained positive 
throughout the trial. Angina occurred in three patients 
during placebo. three during acute patch application, four 
during continuous and one during intermittent treatmenl. 
The behavior of the vartoos exercise end points in the 
different trial phases is shown in Table 2 aad Figure 1. 
Relative to placebo, immediate patch application im- 
proved exercise capacity: time to 1 mm ST segment depres- 
sion increased from 471 + 226 to 590 ?r 213 s (p < O.O.Sl and 
total exercise time also increased From 562 2 227 to 631 ? 
219 s (p = NS). Heart rate, systolic blood pressure and 
Qare 1. Results of exercise stress les!ing. Time to 1 mm of Sf 
segment depression (shtte tram) and total exercise lime ( 
bars) were recorded in each triai phase. Relative to placebo. rime to 
1 mm of ST depression war sigaificrmUy longer during immediale 
patch application (*p < 0.05) and interatittent tmatmcat Jhrlcnn. 
patch) ( p < 0.01). Contin. patch = conunu~as patch apphcabon. 
Table 3. lschemic Episodes Recorded During Hoker Monitoring 
1 3 - I _ 
2 I - 1 _ 
3 2 _ I - 
4 3 2 - 
5 3 6 I 2 
6 3 - 3 _ 
7 I 2 6 _ 
8 i I I 
9 1 I _ 
IO 1 I 1 
II 3 1 3 I 
12 2 I 2 - 
a*MLO Midnight 
Midnight L0SAt.l 
2 1 
I 
5 
4 
I 4 
I 
I 1 
I _ 
I - 
3 t 
2 I 
I 
Cantinuaus IntemdUenl 
aAM: Midnight BAMIO Midnight 
hlldnizhl ulS8.M Midninhr 108bM 
4 - 
I _ 
2 - 
6 
2 I 
I - 
I I 
I 
I 
2 - 
2 3 
4 1 
3 I 3 _ 
I _ 
I - 
2 2 
4 I 
2 _ 
2 I 
I - 
2 I 
I 1 
1 - 
rate-pressure product at the onset of ischemia (I mm ST 
segment depression) and at peak exercise were not signifi- 
cantly diKerent from values with placebo. 
On maintenance intermittent treatment, time to 1 mm of 
ST segment depression and total exercise time (601 + 236 
and 651 + 213 s, respectively) were significantly greater than 
with placebo administration @ < 0.01) but were not signifi- 
cantly different from values during continuous dosing (540 ? 
251 and 610 i- 231 s, respectively, p = NS). During inter- 
mittent dosing, heart rate and systolic blood pressure at 
I mm of ST segment depression (t25 -C 14 beats/mm and 
170 + 11 mm Hg) were higher than with placebo administra- 
tion (117 f !l beats/mm and 160 * 20 mm Hg. respectively, 
p < 0.05), but no significant changes in these variables were 
noted between continuous and intermittent therapy. 
Helter monitoring. The results obtained by ambulatory 
ECG mouitoring during the different treatment phases in 
individual patients are shown in Table 3. In the 60 24-h 
recordings obtained in the 12 patients, we observed a total of 
168 episodes of ischemic ST segment depression, of which 
54 (32%) were associated with an&a: 128 (76%) occurred 
between g AM and midnight and 40 (24%) from midnight to 
8 AM. In the individual patients, the number of ischemic 
episodes during the 24 h ranged from one to nine. 
No statistically significant differences were found in the 
number, severity and duration of iachemic attacks recorded 
during the different trial phases. Of the 168 episodes, 36 
occurred during the no patch period, 34 during placebo 
administration, 32 during immediate patch application and 35 
during continuous and 30 during intermittent treatment (Fii. 
2). Similarly, total ischemic time was 628 min during the no 
patch period, 483 min during placebo administration, 
443 min during active nitroglycerin patch application and 
439 min during continuous and 593 min during intermittent 
treatment (Fig. 3). Similarly, transdermal nitroglycerin 
patches did not affect the diurnal distribution of isehemic 
attacks; in fact. during continuous treatment, the mean 
number of episodes recorded during the daytime (from 8 AM 
to midniuht) and during the niuht (from midniaht to 8 AMI 
was24 2 1.6and0.6 + 1.0, respectively; duri~intennittent 
therapy, an avenge of 1.9 f 1.0 and 0.6 + 0.7 episodes, 
reswctivelv. was recorded. These values were not sinnib- 
tautly diffdrknt from those obtained with placebo (2.J 2 1.5 
and 0.3 f 0.7, respectively). Finaiiy, the ECG severity of 
ischemic episodes apparently was not affected by trauader- 
mal nitroglycerin and the percent of episodes with 1, 2 and 
3 mm of ST segment depression remained practically un- 
changed during the various trial phases. 
Subjective prrmmcnt. Of the 14 patients initially en- 
rolled, 2 discontinued treatment because of severe head- 
ache; in the remaining 12, the nitroglycerin patches were 
welt tolerated. No other side effecta were noted. The overall 
incidence of anginrd attacks during the investigation was low 
and there was no evidence of exacerbation of angina during 
overnight patch removal in the intermittent phase compared 
with the continuous phase. 
Figure 2. lschemic episodes recorded during ambulatory monitor- 
ing. Cshunus indicate the total number of events observed during 
each rrial phase. For each of the I2 patients tllues), the number ef 
ischemic episodes is indicated by paints. Contin. = continuous 
patch applicaiion: Ind. = individual patients: Interm. = intermittent 
patch application; Run-in = no patch. 
10 YI 
Figure 3. Total ischemic lime during ambulatory rlcctmcardic- 
graphic monitoring. T4 ischemic time Imin) rec&ded wcr 24 h in 
each trial phase (see lext). Groupand individual data arc presented. 
Abhreviathms as in Figure 2. 
Despite the lack of objective evidence of anti-ischemic 
effects, daily angina1 episodes were significantly less (p < 
0.05) during both continuous (1.3 + 0.8) and intermittent 
(1.2 ? 0.6) treatment than during placebo (2.2 -?: 1.6). 
Discussion 
Present findings. Our findings confirm and extend the 
results of previous reports and indicate that although nitro- 
glycerin patches afford some improvement in exercise ca- 
pacity in the very early phase of treatment. tolerance rapidly 
develops when these preparations are used continuously. In 
fact, no significant prolongation in exercise duraiion and 
time to ischemia was found when transdermal nitrog!~erin 
was given continuously for 12 days, whereas a slighl but 
statistically significant improvement was observed when the 
patch was removed overnight. 
However, the improvement in exercise tolerance ob- 
sewed with the intermittent dosing schedule was not main- 
tained during daily activities. In fact, analysis of ambulatory 
ECG recordings showed no sigr.ilicant differences among the 
various treatment phases. Neither continuous nor intermit- 
tent administration of transdermal nitroglycerin appeared to 
affect the number, severity, duration and diurnal distribution 
of ischemic events. 
Relation to previous studies. Our data support the results 
obtained by Fox et al. (22). who also studied the effects of 
continuous and intermittent transdermal nitroglycerin and 
used both exercise iesting and ambulatory ST segment 
monitoring as objective end points. However, in that study, 
an&graphic evidence of the presence and severity of coro- 
nary artery disease was not provided and the trial was 
conducted on two separate study groups-one treated con- 
tinuously and the other intermittently. 
The discrepancy between the results of exercise stress 
testing and those obtained by HoAcr monitoring has also 
been reported by others (21,221 and is difficult to explain. It 
could be argued that our study patients were monitored for 
only 24 h and that thrscould have p&ally accounted for OLLI 
negative results. However,, For e! al. (22). who employed a 
48-h monitoring period. &o failed to show a significant 
anti-ischemic effect of transdermal nitroglycerin. It is possi- 
ble that the lack of efficacy on daily life iscbemia relates to 
inconstant drug plasma levels and to the fact that episodes 
occurring during normal activities are probably caused by a 
variety of pathophysiologic mechanisms, not all necessariiy 
prevented by :ransdennal nitrates. 
Surprisingly. despite the tack of objective evidence far 
anti-ischemic effects. the frequency of an@ attacks re- 
pofled during intermittent and contincons trea!rnem was 
significantly lower than with placebo. The observarion is in 
keeping with the results of open studies (28) in which the 
efficacy of rransdermal nitrales was evaluated by the effects 
on symptoms and could be reiated to the reduction incardiac 
volume and left ventricular Ming pressure induced by ni- 
trates. In &CL although the mechanisms of cardiac ischemic 
pam are largely unknown, experimental studies suggest that 
nonspecific “polymodal” receptors (29) and, particularly. 
vcmricular ?tretct receptors activated by changes in preload 
(301 are probably involved in mediating angina. 
A crucial point regarding the use of intermittent nitrate 
preparations relates to the possibility rhat drug withdrawal 
during rrearment-free intervals may exacerbate ischemic 
events. especially if asymptamatic. The results of our study 
do not support this hypothesis and zhow that despite a lower 
nitroglycerin dose delivered over t?e 24 h (6.6 rather than 
t0 mg). !hc rntermittent schedule was nor associ. .d with 
worsening of &hernia. 
Conclusions. Our study confirms and extends previous 
reports (&‘Rt by showing that intermittent transcutaneous 
nitroglycerin dosing does not cause tolerance and improves 
exercise capacity in patients with stabie angoa. Further- 
more. it provides the first objective demonstration that this 
torrnulalion. despite reducing the frequency of anginal at- 
tacks. does not affect the number and severity of silent 
ischemic events rhat occur during normal daily activities 
regardless of the type of dosing schedule. This finding 
suggesls that the anti-ischemic effects of transdermal nitro- 
glycerin are prabdbly IOO mild when the drug is not supple- 
mented by otherantianginal medications. Finally, in patients 
with chronic stable angina, intermittent dosing schedules do 
not appear to cause exacerbation of ischemic events during 
overnight withdrawal. Whether this also applies to more 
severe forms of angina remains to be eslablished. 
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